No. The regulations at 21 CFR 312.53(c)(1)(viii) require only that sub investigators
names be listed in Section #6 of the 1572. It is the responsibility of the sponsor to select
investigators qualified by training and experience, as appropriate experts, to investigate
the drug. The investigator must ensure that all associates, colleagues, and employees
assisting with the conduct of the clinical investigation are aware of their obligations
including complying with the IND regulations.
